Swetha Kambhampati, MD

Videos

Brexucabtagene Autoleucel Treatment for Patients With R/R Mantle Cell Lymphoma: Real-World Outcomes

06/21/2023

At the 2023 ASCO annual meeting, Swetha Kambhampati, MD, provided insights into the real-world outcomes of brexucabtagene autoleucel therapy for patients with relapsed/refractory MCL through a subgroup analysis of outcomes by prior treatment.

At the 2023 ASCO annual meeting,...

06/21/2023

Oncology

Conference Coverage

Real-World Value of Brexucabtagene Autoleucel for Patients With R/R MCL Including High-Risk Features

12/20/2023

Swetha Kambhampati , MD;

At the 65th ASH Annual Meeting, Swetha Kambhampati, MD, shares data on the real-world outcomes of brexucabtagene autoleucel treatment for patients with R/R mantle cell lymphoma, including high-risk subgroups.

At the 65th ASH Annual Meeting,...

12/20/2023

Oncology